Role of Acute Therapy
WAO/EAACI guidelines for treating hereditary angioedema (HAE) recommend that an acute therapy be part of every HAE treatment plan
Patients are strongly encouraged to1:
- Carry acute therapy with them at all times
- Have enough acute treatment for 2 attacks, or at least 2 doses, on hand to be prepared if an attack happens
Treatment of acute HAE attacks should be administered1:
- As early as possible in an attack
- For all attacks, regardless of location, as soon as they are clearly recognized
Review the signs and symptoms of an attack with your patients
- HAE attacks typically cause swelling of the skin/subcutaneous tissues, the gastrointestinal tract/abdomen, and the upper airways, including the larynx.2,3
- Many patients may experience prodromal signs before an HAE attack, including a tingling sensation, erythema marginatum (a mild, nonpruritic rash), fatigue, and nausea2,4
Reevaluate each patient’s treatment plan regularly1
- Make sure your patients are prepared with a detailed treatment plan
- Monitor frequency of attacks and efficacy of treatment
- Patients should be evaluated for long-term preventive treatment at every doctor's visit, or at least once a year
Recommend FIRAZYR for all acute HAE attacks—whether they occur at home or away5
- As the first prefilled, self-administered, subcutaneous injection, FIRAZYR is ready to use as soon as an attack strikes—no reconstitution/mixing, no dose calculation, no special handling, no dose titration, and no refrigeration
- FIRAZYR demonstrated faster symptom relief when compared to placebo in clinical trials
- Nine out of 10 HAE attacks were treated with only one injection of FIRAZYR in clinical trials (n=582) and in an international observational study (n=1657)
- FIRAZYR is a proven bradykinin B2-receptor antagonist used to treat HAE attacks. By inhibiting bradykinin from binding to the B2 receptor, FIRAZYR reduces the clinical symptoms of an acute episodic attack of HAE.
